Grant: Engage Grants Program
Dalhousie University
$24,859.00
Engineering of Stable Cell Lines Expressing TRPV Cation Channel Proteins
EF 2017-18
Résumé
Soricimed Biopharma, Inc. is a Sackville/Moncton, New Brunswick based company developingbiopharmaceutical compounds based on soricidin, a paralytic protein found in the saliva of the NorthernShort-tailed Shrew. SOR-C13, the company's lead compound, is a synthetic, 13-mer peptide whose therapeuticactivity is based on its interaction with a calcium channel, TRPV6, whose expression is elevated in certain celltypes (e.g. cancer cells). Also, derivatives of SOR-C13 (C-peptides) can be used as vehicles to deliver otherdrugs directly into TRPV6-bearing cells. Optimization of this drug delivery platform is hampered by thecurrent lack of a significant in-house tool; a stable cell line overexpressing the TRPV6 channel. Under thisEngage Grant, Dr. Weaver's lab will develop this cell line, allowing Soricimed to determine what properties ofthe C-peptide derivatives improve their interaction with TRPV channels and hence their ability to target andenter cells bearing these channels. This gained knowledge would in turn lead to expansion of the company'sproduct line with new and improved therapeutic C-peptides, and novel C-peptide/drug conjugates targetingspecific cell types. Broadening and solidifying the company's pipeline with such products will lead topartnerships with larger biopharma companies and expand Soricimed's drug marketability.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Nova Scotia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
521672-2017
Name nom
Weaver, Ian
Department département
Psychology and Neuroscience
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
24859
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1551
Committee name en
Atlantic Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Atlantique
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
1
Nb partie
1
Application title
Engineering of Stable Cell Lines Expressing TRPV Cation Channel Proteins
Keyword
NSERC
Application summary
Soricimed Biopharma, Inc. is a Sackville/Moncton, New Brunswick based company developingbiopharmaceutical compounds based on soricidin, a paralytic protein found in the saliva of the NorthernShort-tailed Shrew. SOR-C13, the company's lead compound, is a synthetic, 13-mer peptide whose therapeuticactivity is based on its interaction with a calcium channel, TRPV6, whose expression is elevated in certain celltypes (e.g. cancer cells). Also, derivatives of SOR-C13 (C-peptides) can be used as vehicles to deliver otherdrugs directly into TRPV6-bearing cells. Optimization of this drug delivery platform is hampered by thecurrent lack of a significant in-house tool; a stable cell line overexpressing the TRPV6 channel. Under thisEngage Grant, Dr. Weaver's lab will develop this cell line, allowing Soricimed to determine what properties ofthe C-peptide derivatives improve their interaction with TRPV channels and hence their ability to target andenter cells bearing these channels. This gained knowledge would in turn lead to expansion of the company'sproduct line with new and improved therapeutic C-peptides, and novel C-peptide/drug conjugates targetingspecific cell types. Broadening and solidifying the company's pipeline with such products will lead topartnerships with larger biopharma companies and expand Soricimed's drug marketability.